Clinical trials: Epirubicin
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Early Breast Cancer, Triple Negative Breast Cancer
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Phase II, randomized, Active-controlled open label trial for treatment of high risk, HR-/HER2- (triple negative) breast cancer, with two sequences of neoadjuvant chemotherapy on a background of pembrolizumab
- Trial name
- KEYPARTNER (NCT06371807)
- Testing
- Pembrolizumab injection
- Where
- 3 sites in Portugal
- Volunteers
- 20 people
- Sponsor
- Fundacao Champalimaud
Breast Cancer, HER2 Positive
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
- Trial name
- TRAIN-2 (NCT01996267)
- Testing
- PTC+Pertuzumab, FEC-T+Pertuzumab
- Where
- 33 sites in Netherlands
- Volunteers
- 437 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
- Trial name
- NCT06227117
- Testing
- Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Testicular Neoplasms
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin).
- Trial name
- GAMEC-II (NCT06309732)
- Testing
- Pegfilgrastim, Dactinomycin, Methotrexate
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Queen Mary University of London
Sepsis
Epirubicin for the Treatment of Sepsis & Septic Shock
The study will assess the safety of low doses of epirubicin in sepsis patients. Therefore the study will look for side effects in patients treated with low dose epirubicin compared to control patients.
- Trial name
- EPOS-1 (NCT05033808)
- Testing
- Epirubicin
- Where
- 5 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Jena University Hospital
Breast Cancer, HER2-positive Breast Cancer
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time, becoming the number one cancer in the world. HER2 is an important prognostic indicator and therapeutic target for breast cancer.
- Trial name
- NCT05474690
- Testing
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
- Where
- China
- Sponsor
- Henan Cancer Hospital
Neutropenia, Breast Cancer
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide.
- Trial name
- NCT02527746
- Testing
- F-627, EC regimen
- Volunteers
- 18 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TavIx (NCT00630032)
- Testing
- cyclophosphamide, Docetaxel, epirubicin hydrochloride
- Where
- 86 sites in United States, Belgium and 1 more
- Volunteers
- 762 people
- Sponsor
- UNICANCER
Triple Negative Breast Cancer, Breast Cancer
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
The purpose of this study is to compare the efficacy and safety between docetaxel combined with doxorubicin (epirubicin) and cyclophosphamide followed by gemcitabine combined with cisplatin and doxorubicin (epirubicin) combined…
- Trial name
- NCT02641847
- Testing
- docetaxel, doxorubicin or epirubicin, cyclophosphamide
- Where
- China
- Volunteers
- 503 people
- Sponsor
- Fudan University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Breast Neoplasms
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
The goal of this multicenter, two-cohort, exploratory clinical trial is to evaluate patients with early stage hormone receptor-negative breast cancer receiving standard adjuvant chemotherapy after surgery.
- Trial name
- SMA-BC-002 (NCT05978648)
- Testing
- Trilaciclib, Epirubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- wang shusen
Adenocarcinoma of the Esophagogastric Junction
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Metabolic and Molecular Response evaluation for the individualization of therapy in adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for patients with metabolically (ie, according to PET…
- Trial name
- MEMORI (NCT02287129)
- Testing
- Oxaliplatin, Epirubicin, Capecitabine
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Technical University of Munich
Breast Cancer
Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer
There is clear preclinical in vitro and in vivo evidence of sequence dependent synergy between chemotherapy agents and zoledronic acid.
- Trial name
- ANZAC (NCT00525759)
- Testing
- 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Breast Neoplasms
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis.
- Trial name
- NCT06121570
- Testing
- Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Neoadjuvant Chemotherapy
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Breast cancer is the most common malignant tumor in women. EC-TH is one of the standard chemotherapy regimens for HER-2 positive early breast cancer(EBC). Earlier use of trastuzumab may improve DFS rate.
- Trial name
- NCT04172259
- Testing
- Doxorubicin liposome, Cyclophosphamide, Trastuzumab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Stomach Neoplasms, Gastric Cancer
Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients
Chemotherapy is an important therapeutic method for patients with advanced gastric cancer. However, there is currently no established standard chemotherapeutic regimen in the preoperative or neoadjuvant treatment setting.
- Trial name
- SVOSA (NCT02338518)
- Testing
- oxaliplatin, etoposide, pharmorubicin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Jinling Hospital, China
Breast Cancer, Neoadjuvant Therapy
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.
- Trial name
- NCT05983094
- Testing
- Utidelone, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 181 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Neoplasms
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis.
- Trial name
- NCT05981014
- Testing
- Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Diffuse Large B Cell Lymphoma
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma…
- Trial name
- NCT05887726
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liaoning Cancer Hospital & Institute